Gilead Sciences, Inc. (GILD) Stock Analysis — Fair Value, Risk & Moat Rating
NMS · Healthcare · Drug Manufacturers - General
Is Gilead Sciences, Inc. a safe investment right now?
Gilead Sciences, Inc.'s Altman Z-Score of 4.28 places it in the safe zone. Our fair value estimate is $125.08 (Fairly Valued). Moat rating: 3.4/5 stars.
Could Gilead Sciences, Inc. go bankrupt? Altman Z-Score analysis
Z-Score of 4.28 is above 3.0, indicating the company is financially healthy by this metric.
- Below 1.8 — Distress Zone (high bankruptcy risk)
- 1.8 to 3.0 — Gray Zone (elevated uncertainty)
- Above 3.0 — Safe Zone (financially healthy)
What drives GILD's Z-Score?
| Component | Formula | Value | Weight | Contribution |
|---|---|---|---|---|
| A · Working Capital / Total Assets | WC / TA | 0.1106 | 1.2 | 0.13 |
| B · Retained Earnings / Total Assets | RE / TA | 0.2326 | 1.4 | 0.33 |
| C · EBIT / Total Assets | EBIT / TA | 0.1833 | 3.3 | 0.6 |
| D · Market Cap / Total Liabilities | MCap / TL | 4.5311 | 0.6 | 2.72 |
| E · Revenue / Total Assets | Rev / TA | 0.4988 | 1.0 | 0.5 |
How has GILD's financial health changed over time?
| Year | Z-Score | Zone |
|---|---|---|
| 2022 | 3.55 | Safe |
| 2023 | 3.82 | Safe |
| 2024 | 3.49 | Safe |
| 2025 | 4.28 | Safe |
Source: Calculated from GILD's latest 10-K filing on SEC EDGAR.
What is Gilead Sciences, Inc. actually worth?
How we calculated this
| Input | Value | Source |
|---|---|---|
| Predicted EPS (α) | $7.49 | Proprietary blend of reported actuals + analyst consensus, weighted by α |
| Last Year EPS | $6.78 | Annual report (SEC EDGAR) |
| Analyst Consensus EPS (This Year) | $8.56 | 28 analysts consensus |
| Trailing P/E | 19.6x | Current market pricing |
| Fair P/E (β discount) | 16.7x | Trailing PE adjusted by value discount factor β, hard-capped |
| Earnings Trend (γ) | Growing | Directional signal: predicted vs trailing EPS |
Wall Street Reference: Analyst consensus target price is $158.36 (28 analysts). This is shown for reference only and is not used in our valuation model.
Source: Earnings data from SEC EDGAR filings. Market data via Yahoo Finance.
Does Gilead Sciences, Inc. have a durable competitive advantage?
Moat rating: 3.4/5.
What makes up GILD's moat score?
ROIC Stability
ROIC variability over the past decade. Score: 4/5.
Gross Margin Trend
Gross margin trajectory over the past decade. Score: 3/5.
Switching Costs
Estimated customer lock-in based on margin level. Score: 3/5.
How stable is GILD's return on invested capital?
| Year | ROIC | Trend |
|---|---|---|
| 2022 | 14.5% | — |
| 2023 | 16.3% | Rising |
| 2024 | 3.6% | Declining |
| 2025 | 22.7% | Rising |
Source: ROIC calculated from SEC EDGAR filings.
Is Gilead Sciences, Inc.'s dividend safe?
Can Gilead Sciences, Inc. afford its dividend?
Payout ratio is 46.6%. FCF covers the dividend 2.2x. 12 consecutive years of payments.
Gilead Sciences, Inc.'s key financial metrics
| Metric | Latest | 1Y Ago | 3Y Ago | Trend |
|---|---|---|---|---|
| Revenue | $29.4B | $28.8B | $27.3B | Rising |
| Net Income | $8.5B | $0.5B | $4.6B | Rising |
| Free Cash Flow | $9.5B | $10.3B | $8.3B | Rising |
| Gross Margin | 78.8% | 78.3% | 79.3% | Stable |
Recent events that affect our GILD analysis
GILD earnings report scheduled
Upcoming report. Consensus EPS estimate: $1.91. Revenue estimate: $6.92B. Our current Fair Value: $125.08 — a significant beat or miss could shift this estimate.
GILD analyst consensus: 73% bullish (22 of 30 analysts)
5 Strong Buy, 17 Buy, 8 Hold, 0 Sell, 0 Strong Sell. Consensus target: $158.36 (19.2% upside). Compare with our independent Fair Value: $125.08.
GILD paid $0.8200/share dividend
Dividend Safety Grade: A. Payout ratio: 46.6%.
GILD filed annual report (10-K)
Annual filing with full-year financials. Our Altman Z-Score, Moat, and Fair Value models are derived from this data. View on SEC EDGAR →
GILD filed 8-K (material event)
8-K filings disclose material events — acquisitions, leadership changes, or guidance revisions that may affect valuation. View on SEC EDGAR →
GILD beat EPS estimates by 12.7%
Reported EPS: $1.74 vs estimate $1.54. Earnings strength supports our Fair Value of $125.08 (5.9% below current price).
GILD filed 8-K (material event)
8-K filings disclose material events — acquisitions, leadership changes, or guidance revisions that may affect valuation. View on SEC EDGAR →
GILD paid $0.7900/share dividend
Dividend Safety Grade: A. Payout ratio: 46.6%.
GILD filed 8-K (material event)
8-K filings disclose material events — acquisitions, leadership changes, or guidance revisions that may affect valuation. View on SEC EDGAR →
GILD filed quarterly report (10-Q)
Quarterly update with interim financials. May signal changes to earnings trajectory and balance sheet health. View on SEC EDGAR →
GILD beat EPS estimates by 43.5%
Reported EPS: $2.43 vs estimate $1.69. Earnings strength supports our Fair Value of $125.08 (5.9% below current price).
GILD filed 8-K (material event)
8-K filings disclose material events — acquisitions, leadership changes, or guidance revisions that may affect valuation. View on SEC EDGAR →
GILD filed 8-K (material event)
8-K filings disclose material events — acquisitions, leadership changes, or guidance revisions that may affect valuation. View on SEC EDGAR →
GILD paid $0.7900/share dividend
Dividend Safety Grade: A. Payout ratio: 46.6%.
GILD filed 8-K (material event)
8-K filings disclose material events — acquisitions, leadership changes, or guidance revisions that may affect valuation. View on SEC EDGAR →
GILD beat EPS estimates by 5.1%
Reported EPS: $1.56 vs estimate $1.48. Earnings strength supports our Fair Value of $125.08 (5.9% below current price).
GILD filed quarterly report (10-Q)
Quarterly update with interim financials. May signal changes to earnings trajectory and balance sheet health. View on SEC EDGAR →
GILD filed 8-K (material event)
8-K filings disclose material events — acquisitions, leadership changes, or guidance revisions that may affect valuation. View on SEC EDGAR →
GILD filed 8-K (material event)
8-K filings disclose material events — acquisitions, leadership changes, or guidance revisions that may affect valuation. View on SEC EDGAR →
GILD paid $0.7900/share dividend
Dividend Safety Grade: A. Payout ratio: 46.6%.
GILD filed 8-K (material event)
8-K filings disclose material events — acquisitions, leadership changes, or guidance revisions that may affect valuation. View on SEC EDGAR →
GILD filed quarterly report (10-Q)
Quarterly update with interim financials. May signal changes to earnings trajectory and balance sheet health. View on SEC EDGAR →
GILD beat EPS estimates by 1.9%
Reported EPS: $1.81 vs estimate $1.78. Earnings strength supports our Fair Value of $125.08 (5.9% below current price).
GILD filed 8-K (material event)
8-K filings disclose material events — acquisitions, leadership changes, or guidance revisions that may affect valuation. View on SEC EDGAR →
GILD paid $0.7900/share dividend
Dividend Safety Grade: A. Payout ratio: 46.6%.
GILD filed 8-K (material event)
8-K filings disclose material events — acquisitions, leadership changes, or guidance revisions that may affect valuation. View on SEC EDGAR →
GILD filed annual report (10-K)
Annual filing with full-year financials. Our Altman Z-Score, Moat, and Fair Value models are derived from this data. View on SEC EDGAR →
GILD beat EPS estimates by 11.7%
Reported EPS: $1.90 vs estimate $1.70. Earnings strength supports our Fair Value of $125.08 (5.9% below current price).
GILD filed 8-K (material event)
8-K filings disclose material events — acquisitions, leadership changes, or guidance revisions that may affect valuation. View on SEC EDGAR →
Common questions about Gilead Sciences, Inc.
What is Gilead Sciences, Inc. stock price today?
Gilead Sciences, Inc. (GILD) stock price is $132.90 as of the latest market close, traded on the NASDAQ exchange.
What does Gilead Sciences, Inc. do?
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. It provides Biktarvy, Descovy, Genvoya, Odefsey, Sunlenca, Symtuza, and YeztugoFor the treatment of HIV-1 infection in patients. It also provides Epclusa, Livdelzi, and Vemlidy to treat chronic hepatitis C virus, primary biliary cholangitis, and chronic hepatitis B virus; Tecartus, a T-cell therapy for the treatment of adult patients; Trodelvy, an injection for intravenous use; and Yescarta, a suspension for intravenous infusion, is a CAR T-cell therapy for the treatment of adult patients.
What is Gilead Sciences, Inc. market cap?
Gilead Sciences, Inc. has a market capitalization of $164.96B, classifying it as a large-cap stock in the Healthcare sector.
What sector and industry is GILD in?
Gilead Sciences, Inc. operates in the Healthcare sector, specifically within the Drug Manufacturers - General industry. It trades on the NASDAQ under the ticker symbol GILD.
Is GILD stock overvalued or undervalued?
Based on our valuation model, Gilead Sciences, Inc. trades 6.2% above our fair value estimate — potentially overvalued.
- FairValueLabs Fair Value: $125.08
- Current Price: $132.90
- Valuation Zone: Fairly Valued
What is GILD stock forecast and analyst target price?
Based on 28 Wall Street analysts, the consensus price target for Gilead Sciences, Inc. is $158.36, implying upside of 19.2% from the current price.
- Analyst High Target: $180.00
- Analyst Low Target: $123.00
Note: Analyst targets are shown for reference and are not used in our valuation model.
Is Gilead Sciences, Inc. revenue and earnings growing?
Here are the analyst consensus growth estimates for Gilead Sciences, Inc.:
- Revenue growth (current year est.): 2.6%
- EPS growth (current year est.): 5.0%
- Revenue growth (next year est.): 6.1%
- EPS growth (next year est.): 12.4%
What are Gilead Sciences, Inc.'s key financial metrics?
| Metric | Latest | Trend |
|---|---|---|
| Revenue | $29.4B | Rising |
| Net Income | $8.5B | Rising |
| Free Cash Flow | $9.5B | Rising |
| Gross Margin | 78.8% | Stable |
What is GILD's P/E ratio?
The price-to-earnings ratio measures how much investors pay per dollar of earnings:
- Trailing P/E (last 12 months): 19.6x
- Forward P/E (next 12 months est.): 13.8x
- FairValueLabs Fair P/E: 16.7x
How volatile is GILD stock?
Gilead Sciences, Inc. has a beta of 0.40, meaning it is less volatile than the broader market. A beta above 1.0 indicates higher price swings relative to the S&P 500, while below 1.0 suggests more stability.
How much cash and debt does Gilead Sciences, Inc. have?
Gilead Sciences, Inc.'s balance sheet shows:
- Total Cash: $9.61B
- Total Debt: $25.54B
- Net Cash Position: $-15.93B
A positive net cash position means the company holds more cash than debt, reducing financial risk.
What is Gilead Sciences, Inc.'s free cash flow?
Gilead Sciences, Inc. generated $7.54B in trailing twelve-month free cash flow (from $10.02B in operating cash flow). Free cash flow represents the cash available for dividends, buybacks, and debt reduction after all capital expenditures.
Does Gilead Sciences, Inc. pay a dividend, and is it safe?
Yes, Gilead Sciences, Inc. pays a regular dividend. Here are the key metrics:
- Dividend Yield: 2.4%
- Payout Ratio: 46.6%
- Consecutive Years Paid: 12
- 5-Year Dividend Growth: -22.0%
- FairValueLabs Safety Grade: A
Is Gilead Sciences, Inc. at risk of going bankrupt?
Gilead Sciences, Inc.'s Altman Z-Score is 4.28, placing it in the safe zone (above 3.0) — bankruptcy risk is low. The Z-Score uses five balance sheet ratios to predict bankruptcy probability within two years.
Does Gilead Sciences, Inc. have a durable competitive advantage?
Gilead Sciences, Inc. scores 3.4/5 stars (Narrow moat) in our moat analysis:
- ROIC Stability: 4/5
- Gross Margin Trend: 3/5
- Switching Costs: 3/5
A score above 3.5 suggests meaningful pricing power and a defensible market position.
What is GILD's return on equity (ROE)?
Gilead Sciences, Inc.'s return on equity is 40.7%. ROE measures how efficiently a company generates profits from shareholder equity. An ROE above 15% is generally considered strong, while below 10% may signal inefficiency.
How do I buy GILD stock?
GILD shares can be purchased through any brokerage account that provides access to the NASDAQ. Common steps:
- Open an account with a broker (e.g., Fidelity, Schwab, Interactive Brokers)
- Search for ticker symbol GILD
- Place a market or limit order for your desired number of shares
This is not investment advice. Always do your own research before buying any stock.
Is GILD a value stock or speculative?
FairValueLabs classifies Gilead Sciences, Inc. as Value Investment. It exhibits consistent profitability, reasonable valuation, and financial stability — characteristics of a traditional value investment.
Who is the CEO of Gilead Sciences, Inc.?
The current CEO of Gilead Sciences, Inc. is Mr. Daniel P. O'Day.
What is GILD's earnings per share (EPS)?
Earnings per share measures the company's profit allocated to each outstanding share:
- Trailing EPS (last 12 months): $6.78
- Forward EPS (next 12 months est.): $9.62
- Analyst consensus EPS (this year): $8.56
- Analyst consensus EPS (next year): $9.62
Other Healthcare companies analyzed by FairValueLabs
FairValueLabs Disclaimer
All valuations, scores, ratings, and classifications on this page are produced by the FairValueLabs internal valuation system. They do not represent actual market value, guaranteed outcomes, or professional investment advice. These are analytical estimates for educational and research purposes only.
This is not financial advice. All data is sourced from SEC EDGAR public filings. Always consult a qualified financial advisor before making investment decisions.
Last updated: Apr 22, 2026. Data sources: SEC EDGAR (financial statements), Yahoo Finance (market data, analyst consensus). Data may not reflect the most recent quarter.
GILD analysis methodology: How we calculate fair value, Z-Scores, and moat ratings